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Background: In patients with platinum-sensitive recurrent serous ovarian cancer 
(PSR SOC), maintenance monotherapy with the PARP inhibitor olaparib 
(Lynparza™) significantly improves progression-free survival (PFS) versus placebo. 
We assessed the effect of maintenance olaparib on overall survival (OS) in patients 
with PSR SOC, including those with BRCA1/2 mutations (BRCAm).  
Methods: In this Phase II trial, patients had PSR SOC, had received ≥2 courses of 
platinum-based chemotherapy and responded to their latest regimen. Patients were 
randomised, using a computer-generated sequence, to oral maintenance olaparib 
(400 mg twice daily; capsules) or placebo by an interactive voice response system, 
stratified by ancestry, time to progression on penultimate platinum and response to 
most recent platinum. The primary endpoint was PFS. Here, we present data for OS, 
a secondary endpoint, from the third data analysis after >5 years’ follow-up 
(intention-to-treat population). Randomised patients were analysed for OS; treated 
patients were analysed for safety. This trial is ongoing and is registered with 
ClinicalTrials.gov (NCT00753545). 
Findings: Between 28 August 2008 and 9 February 2010, 136 patients were 
randomised to olaparib and 129 to placebo. 136 patients had deleterious BRCAm. 
The data cut-off for this analysis was 30 September 2015. An OS advantage was 
observed with maintenance olaparib versus placebo in all patients (HR 0·73 [95% CI 
0·55–0·96]; median OS 29·8 vs 27·8 months) and BRCAm patients (HR 0·62 [0·41–
0·94]; 34·9 vs 30·2 months). 11 (15%) of 74 BRCAm patients received maintenance 
olaparib for ≥5 years. Overall, common grade ≥3 adverse events (AEs) were fatigue 
(olaparib: 11/136 patients [8%]; placebo: 4/128 [3%]) and anaemia (olaparib: 8/136 
patients [6%]; placebo: 1/128 [1%]). Serious AEs were reported in 30/136 patients 
(22%) on olaparib and 11/128 patients (9%) on placebo. In patients treated for ≥2 
years, AEs included low-grade nausea (olaparib: 24/32 patients [75%]; placebo: 2/5 
patients [40%]), fatigue (18/32 [56%]; 2/5 [40%]), vomiting (12/32 [38%]; 0) and 
anaemia (8/32 [25%]; 1/5 [20%]); generally, events were initially reported during the 
first 2 years of treatment.  
4 
Interpretation: An OS advantage was seen for patients with BRCAm PSR SOC 
receiving olaparib maintenance monotherapy after platinum-based chemotherapy, 
supporting the reported PFS benefit. Significant long-term exposure to olaparib was 
observed. There were no new safety signals. Taken together, these data support 
both the long-term clinical benefit and tolerability of maintenance olaparib in BRCAm 




Ovarian cancer is the fifth most common type of cancer for women in developed 
countries.1,2 Approximately 70% of patients relapse within 3 years of completing first-
line chemotherapy and the mean 5-year survival rate in Europe is low when 
compared with other tumour types (approximately 38%).3–5 Overall, ovarian cancer is 
the sixth highest cause of cancer-related deaths for women in developed 
countries.1,2  
Olaparib (Lynparza™) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor that 
has demonstrated significant clinical activity in ovarian cancer, particularly in tumours 
that have mutations in BRCA1/2 (BRCAm).6–8 Olaparib traps PARP at sites of DNA 
damage, blocking base-excision repair and resulting in the collapse of DNA 
replication forks and the accumulation of DNA double-strand breaks.9 Induced 
synthetic lethality is observed with olaparib in tumours that are deficient in 
homologous recombination repair (HRR) pathways, such as those with BRCAm.10,11 
Previously, we reported data from a Phase II, randomised, double-blind trial 
(NCT00753545, D0810C00019 [Study 19]) that demonstrated a statistically 
significant improvement in progression-free survival (PFS) for patients with platinum-
sensitive, recurrent serous ovarian cancer (PSR SOC) who received olaparib 
maintenance monotherapy, compared with placebo (hazard ratio [HR] 0·35, 95% 
confidence interval [CI] 0·25–0·49, P<0·0001).6,7 A pre-planned analysis of the 
retrospectively identified BRCAm subgroup showed patients with a BRCAm derived 
the greatest PFS benefit from olaparib (HR 0·18, 95% CI 0·10–0·31, P<0·0001).7 A 
significant improvement in time to first subsequent therapy or death (TFST) and time 
to second subsequent therapy or death (TSST) was also observed with maintenance 
olaparib compared with placebo.7 Based on these data, olaparib (400 mg twice daily 
[bid]; capsules) was approved in the EU as maintenance therapy for patients with 
platinum-sensitive, relapsed, BRCA-mutated ovarian cancer.12 Olaparib is also 
approved in the US as monotherapy for patients with germline BRCA-mutated 
advanced ovarian cancer.13 This indication was based on data from another Phase II 
study (NCT01078662, D0810C00042 [Study 42]).8  
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Two interim analyses of overall survival (OS) from Study 19 have previously been 
conducted, at 38% data maturity (HR 0·94, 95% CI 0·63–1·39, P=0·75) and 58% 
data maturity (HR 0·88, 95% CI 0·64–1·21, P=0·44) in the overall study 
population.6,7 Here, we present an updated descriptive OS analysis following the 
deaths of 203 (77%) of 265 patients in this study, with an additional 3 years of OS 
follow-up since the previous analysis. We assessed the impact of maintenance 






Study design and participants 
Study 19 was a Phase II, randomised, double-blind, placebo-controlled, multicentre 
trial, involving 82 sites across 16 countries. The institutional review boards or 
independent ethics committees of all investigational sites approved the protocol. The 
study was conducted in accordance with the Declaration of Helsinki, Good Clinical 
Practice and the AstraZeneca policy on bioethics.14  
Eligible patients were aged ≥18 years, with recurrent ovarian, fallopian tube or 
primary peritoneal cancer that had high-grade (grade 2 or 3) serous features or a 
serous component and was platinum-sensitive (no disease progression in the first 
6 months after the last dose of the penultimate line of platinum-based 
chemotherapy). Patients must have received at least two prior courses of platinum-
based chemotherapy and had to have shown a complete or partial response to their 
most recent regimen according to Response Evaluation Criteria in Solid Tumors 
(RECIST) v1·0 or Gynecological Cancer InterGroup criteria. Additional eligibility 
criteria have been described.6 All patients provided written informed consent. 
Known BRCAm status was not required for eligibility, but was established via case 
report forms (CRF) documenting previous local germline BRCA testing, or via 
retrospective germline BRCA testing (Integrated BRACAnalysis assay [Myriad 
Genetics, Salt Lake City, UT, USA]) or tumour BRCA testing (next-generation 
sequencing [Foundation Medicine, Cambridge, MA, USA]), as described previously.7 
Those patients whose BRCAm status was established during the study provided 
consent and samples at study entry.  
Randomisation and masking  
Patients were randomised (1:1) to receive olaparib or placebo within 8 weeks 
following completion of their most recent platinum-based regimen. An interactive 
voice response system (IVRS) assigned patients to their treatment, using a 
randomisation scheme generated by a computer program (GRand). The investigator 
who enrolled patients contacted an IVRS centralised randomisation office by 
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telephone for allocation of randomised treatment. Randomisation was stratified by 
ancestry (Jewish vs non-Jewish), time to progression from completion of penultimate 
platinum-based regimen (6–12 months vs >12 months) and response to most recent 
platinum-based regimen (complete vs partial response). 
Treatment assignment was masked from patients and from anyone administering 
interventions, assessing outcomes or analysing data, by the use of unique identifiers 
generated during randomisation. Olaparib and placebo capsules were identical in 
appearance and packaging.  
Procedures  
Patients received oral olaparib maintenance monotherapy, at 400 mg bid (capsules; 
manufactured by AstraZeneca, Macclesfield, UK or Lonza, Visp, Switzerland) or 
matching placebo. Treatment continued until disease progression, provided that 
toxicities were manageable. After progression, patients could continue on study 
treatment if deemed appropriate by the investigator. Crossover between treatment 
arms within the study was not allowed. Dose modifications that were specified for 
toxicity management have been described previously.6 
Tumours were assessed by computed tomography scans or magnetic resonance 
imaging every 12 weeks until week 60 and every 24 weeks thereafter until objective 
disease progression, unless patients withdrew consent. RECIST data were not 
collected after the primary data cut-off (DCO) of 30 June 2010. Patients were 
monitored for OS, with follow-up every 12 weeks after discontinuation of treatment. 
Safety and tolerability were monitored for patients remaining on study treatment by 
record of adverse events (AEs), physical examination, vital signs and laboratory 
findings. AEs were graded using the National Cancer Institute’s Common 
Terminology Criteria for Adverse Events v3·0.  
Outcomes 
We have previously reported data for PFS, which represented the primary endpoint 
for this study.6 OS was a secondary endpoint, but represents the main outcome for 
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this descriptive analysis. Safety, tolerability, TFST and TSST were also assessed. 
Additional endpoints have been described previously.6,7  
Statistical analysis 
Study 19 was sized to ensure a sufficient number of PFS events in the overall study 
population.7 OS was analysed on an intention-to-treat basis. The analysis set for OS 
included all randomised patients and the analysis sets for safety, TFST and TSST 
included all patients who received at least one dose of treatment. Other than for OS, 
no adjustments were made for multiplicity introduced by analysing multiple endpoints 
(TFST and TSST). No adjustments were made for analyses within the BRCAm or 
BRCA wild-type (BRCAwt) subgroups. Two previous analyses of OS have been 
conducted, at 38% data maturity (DCO: 31 October 2011; alpha [two-sided] = 0·1%) 
and 58% data maturity (DCO: 26 November 2012; alpha [two-sided] = 3%).6,7 The 
updated OS analysis described here was conducted at 77% data maturity, using an 
alpha (two-sided) of 0·95%. This OS analysis is considered to be descriptive and the 
P-values are nominal. Exploratory analyses of TFST and TSST were previously 
performed at the 2012 DCO, when these endpoints had 80% and 74% data maturity, 
respectively.7  
OS, TFST and TSST were analysed using a Cox proportional hazards model, which 
was adjusted for treatment, ancestry (Jewish vs non-Jewish), time to progression 
from completion of penultimate platinum-based regimen (6–12 vs >12 months) and 
response to most recent platinum-based regimen (complete vs partial response). 
Restricted means analyses were performed for the OS data using the pseudovalues 
method, as previously described.15 All analyses used SAS v8.2 except the restricted 
means analyses, which used the Comprehensive R Archive Network “pseudo” 
software. This study is registered with ClinicalTrials.gov, number NCT00753545.  
Role of the funding source 
The corresponding author (JAL) designed the study in collaboration with the 
sponsor, AstraZeneca. AstraZeneca authors (AF, SS, PR, EL, DH and MAS) 
collected and analysed the data and had a role in data interpretation and manuscript 
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writing. All authors had access to the raw data. The decision to submit the 
manuscript for publication was made by all authors. The corresponding author (JAL) 
had full access to all of the data and the final responsibility to submit for publication.  
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Results  
Patient enrolment occurred between 28 August 2008 and 9 February 2010. Of the 
326 patients who enrolled, 265 met the eligibility criteria; 136 of these patients were 
randomised to olaparib and 129 were randomised to placebo (Figure 1). BRCAm 
status was established for 254/265 patients (96%), of whom 136 (51% of 265 
patients in the overall study population) had a known or suspected deleterious 
BRCAm. Patient demographics and baseline characteristics were generally well 
balanced for the overall study population, BRCAm and BRCAwt subgroups (Table 
1). The efficacy analysis set included all 265 randomised patients. One patient who 
was randomised to placebo withdrew consent and withdrew from the study without 
receiving treatment; therefore, the analysis sets for safety, TFST and TSST included 
the 264 patients who were treated.  
The DCO for this updated OS analysis was 30 September 2015 (OS data maturity: 
77%). At this DCO, the median follow-up for OS was 71·0 months (inter-quartile 
range [IQR] 67·8–72·9 months) for the overall study population (olaparib: 71·0 
months [68·5–72·7] vs placebo: 70·8 months [38·2–73·0]). This represents an 
additional 3 years of follow-up since the previously reported OS.7 The Cox 
proportional hazards analyses indicate an OS advantage for patients who received 
olaparib maintenance monotherapy compared with patients who received placebo 
(HR 0.73, 95% CI 0.55–0.96, nominal P=0.025; Figure 2a), although this did not 
meet the required threshold for statistical significance (P<0.0095). The BRCAm 
subgroup data (70% OS data maturity) indicate an OS advantage for BRCAm 
patients who were treated with maintenance olaparib (HR 0.62, 95% CI 0.41–0.94, 
nominal P=0.025; Figure 2b). The OS data for the BRCAwt subgroup (84% OS data 
maturity) were: HR 0.83, 95% CI 0.55–1.24, nominal P=0.37 (Figure 2c).  
Most patients in the BRCAm subgroup had germline BRCAm (gBRCAm), but 20 
(15%) of 136 (olaparib: n=10, placebo: n=10) had somatic BRCAm (sBRCAm) only. 
We previously reported 18 sBRCAm patients in Study 19, based on data from 
tumour and blood testing, and 22 patients with tumour BRCAm for whom no blood 
testing data were available.7 Subsequently, we used an algorithm to distinguish 
gBRCAm and sBRCAm based solely on tumour sequencing data and identified the 
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20 sBRCAm patients who are discussed here: this group includes six of the 22 
patients for whom blood testing data were unavailable and 14 of the original 18 
sBRCAm patients.16 Four patients from the previously reported subgroup were 
therefore not included, three as a result of likely incomplete CRF-reported local 
blood-based gBRCAm tests and one as a result of discordant variant results, which 
revealed that the blood and tumour samples were from different individuals. Figure 3 
shows the OS data for the overall, BRCAm, gBRCAm and sBRCAm populations. 
The sBRCAm subgroup data are not inconsistent with those from the other 
subgroups, but there are too few events in this group to draw conclusions. Figure 3 
also shows the BRCA1m and BRCA2m OS data, and Kaplan-Meier survival curves 
for these two subgroups are presented in the Supplementary Material (page 2). 
Formal tests of the proportionality of the hazards, using the methods of Grambsch 
and Therneau, indicated that there was insufficient evidence to dismiss the 
proportional hazards assumption in either the overall population (P=0.19) or the 
BRCAm subgroup (P=0.70).17 However, restricted means analyses were also 
performed, in order to enhance our understanding of average patient survival and 
the effect of study treatment. Table 2 shows the results from these restricted means 
analyses for the overall population and the BRCAm subgroup. These data are 
supportive of the OS advantage with olaparib indicated by the Cox proportional 
hazards analysis. In addition, the Supplementary Material (page 3) shows the 
restricted means data using two alternative methodologies, which gave similar 
estimates for the restricted mean OS. Log-rank test analyses were also consistent 
with the Cox proportional hazards analysis (Table 2).  
Updated exploratory analyses were conducted for TFST and TSST; since the 
previous analysis, the data maturity had increased from 80% to 86% for TFST and 
from 74% to 84% for TSST.7 The median follow-up for TFST was 70.8 months (IQR 
12.6–72·7 months) for the overall population (olaparib: 70.8 months [14.6–72·6] vs 
placebo: 39.0 months [4.1–74.7]); median follow-up for TSST was 70.5 months (IQR 
11.2–72.8 months) for the overall population (olaparib: 70.9 months [16.4–72.6) vs 
placebo: 7.8 months [5.2–72.8 months). Median TFST and TSST were significantly 
prolonged with olaparib compared with placebo, in the overall study population, 
BRCAm and BRCAwt subgroups (Figure 4).  
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At the DCO for this updated OS analysis, 15 (11%) of 136 patients were continuing 
to receive olaparib, eight of whom had a BRCAm. Within this group, the initial dose 
(olaparib 400 mg bid) was being received by nine patients (five BRCAm) and a 
reduced dose of 200 mg bid was being received by six patients (three BRCAm), four 
of whom had a dose reduction owing to AEs. One patient, with a BRCAm, was still 
receiving placebo (<1% of 129). Overall, 18 (13%) of 136 patients had received 
olaparib for ≥5 years (Table 3): 11 of these patients had a BRCAm (15% of 74) and 
seven were in the BRCAwt subgroup (12% of 57). Baseline characteristics for the 
patients who received study treatment for ≥5 years are listed in Table 4.  
Subsequent cancer therapies had been received by 89 (65%) of 136 patients from 
the olaparib arm (45 of 74 BRCAm patients [61%]) and 111 (86%) of 129 patients 
from the placebo arm (55 of 62 BRCAm patients [89%]). From the placebo arm, 17 
(13%) of 129 patients had received post-discontinuation PARP inhibitor (PARPi) 
treatment, of whom 14 (23%) of 62 patients had a BRCAm. These data include one 
additional patient who had received subsequent PARPi therapy since the previous 
DCO (26 November 2012). No patients from the olaparib arm had received 
subsequent PARPi treatment.  
There were no new safety findings in the overall study population when compared to 
those that have previously been reported.6,7 Figure 5a shows the most common AEs 
reported between the start of treatment and the 2015 DCO by patients in the overall 
population who received treatment for ≥2 years. For the 32 patients who received 
olaparib for ≥2 years, 30 (94%) of 32 reported at least one AE, with 15 (47%) of 32 
reporting AEs of grade ≥3. For patients who received olaparib treatment for ≥2 years, 
the frequencies of previously reported common AEs, such as low-grade nausea, 
fatigue, vomiting and anaemia, were consistent with the frequencies that were 
previously reported in the overall population. In general, these AEs were initially 
reported during the first 2 years of treatment. Twenty-one BRCAm patients received 
olaparib for ≥2 years and this subgroup had a similar safety profile to the overall 
group of 32 patients. All five patients who received placebo for ≥2 years reported at 
least one AE; one (20%) of five reported AEs of grade ≥3. Figure 5b shows the 
common AEs reported after 2 years by patients who received treatment for ≥2 years. 
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Twenty-three of the 32 patients who received olaparib for ≥2 years reported AEs 
after 2 years (72%), with 8 (25%) of 32 reporting AEs of grade ≥3. Four of the five 
patients who received placebo for ≥2 years reported AEs after 2 years; none 
reported AEs of grade ≥3. Fifteen of the 32 patients who received olaparib for ≥2 
years had dose reductions (47%), eight of whom (25%) had dose reductions owing 
to AEs. One patient from the placebo arm (20% of five) had dose reductions, which 
were not related to AEs. Three of the patients who received olaparib for ≥2 years 
discontinued treatment owing to AEs, which were: pharyngitis and pancytopenia (two 
AEs in one patient); squamous cell carcinoma of the oral cavity and bronchiectasis 
(each in one patient). None of the patients who received placebo for ≥2 years 
discontinued owing to AEs.  
In the overall study population, the most common grade ≥3 AEs were fatigue 
(olaparib: 11/136 patients [8%]; placebo: 4/128 [3%]) and anaemia (olaparib: 8/136 
patients [6%]; placebo: 1/128 [1%]). Overall, 59 (43%) of 136 patients from the 
olaparib arm and 29 (23%) of 128 from the placebo arm had dose reductions. Dose 
reductions owing to AEs were reported in 34/136 (25%) and 5/128 (4%) patients 
from the olaparib and placebo arms, respectively. AEs that led to discontinuation of 
treatment were reported for eight (6%) of 136 patients from the olaparib arm and two 
(2%) of 128 patients from the placebo arm; all of these AEs were considered to be 
related to treatment. For the olaparib arm, in addition to the AEs that led to late 
discontinuation after 2 years of treatment, the other AEs resulting in discontinuation 
were: palpitations and myalgia (two AEs in one patient); herpes zoster, nausea, 
erythematous rash and haemorrhagic stroke (each in one patient). In the placebo 
arm, the AEs resulting in discontinuation of treatment were pruritic rash and nausea 
(each in one patient). Thirty (22%) of 136 patients and 11 (9%) of 128 patients 
reported serious AEs in the olaparib and placebo arms, respectively. There were no 
additional reports of AEs resulting in death at the 2015 DCO compared with the 2012 
DCO, at which one patient had died solely from AEs (haemorrhagic stroke and 
thrombocytopenia, considered to be treatment-related). Overall, 202 patients in the 
safety analysis set had died at the 2015 DCO (olaparib arm: n=94; placebo arm: 
n=108). In the olaparib arm, 83 patients died only from the disease under 
investigation; one patient had AEs leading to death (haemorrhagic stroke and 
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thrombocytopenia); one patient died from a combination of their underlying disease 
and an AE (myelodysplastic syndrome); and nine patients died from other reasons 
(cardiac failure [n=1], euthanasia [n=1], septic shock [n=1], cerebrovascular disorder 
[n=1], cerebral haemorrhage [n=1] or unknown [n=4]). In the placebo arm, 99 
patients died only from the disease under investigation and nine patients died from 
other reasons (acute renal failure and pneumonia [n=1], pulmonary embolism [n=1], 
cardiopulmonary failure [n=1], septic shock due to faecaloma [n=1], ovarian cancer 
[n=1] or unknown [n=4]). In total, three cases of myelodysplastic syndromes/acute 
myeloid leukaemia (MDS/AML; two in the olaparib arm and one in the placebo arm) 
have been reported. All three of the patients who reported MDS/AML had received 
two prior lines of chemotherapy. Two of these patients had received olaparib 
maintenance monotherapy for 57 and 10 months, respectively, and one had received 




These updated descriptive OS analyses indicate an OS advantage for patients with 
PSR SOC who received olaparib maintenance monotherapy compared with placebo 
in Study 19. The OS data support the previously published results from Study 19, 
which showed that PFS, TFST and TSST are significantly prolonged with olaparib, 
particularly in BRCAm patients.6,7 Although a statistically significant improvement in 
OS was not demonstrated, we observed that olaparib had a beneficial treatment 
effect on OS in the overall population (HR=0.73). This was primarily driven by the 
treatment effect in the BRCAm subgroup, who received the greatest OS benefit from 
olaparib (HR=0.62). The Kaplan-Meier survival curves for the two treatment arms 
begin to separate from approximately 42 months after randomisation for the overall 
study population (Figure 2a). This observation may be a consequence of the 
heterogeneous nature of the overall population and the different treatment effect in 
BRCAm and BRCAwt patients. As BRCAm patients receive the most benefit from 
olaparib and have a better prognosis than BRCAwt patients, the proportion of 
BRCAm to BRCAwt patients at risk increases over time. At the tail end of the survival 
curve for the overall population, there are therefore relatively fewer BRCAwt patients 
at risk and so the treatment effect in BRCAm patients is less diluted, resulting in the 
observed separation. The separation of the survival curves at the tail end also 
suggests the observed OS advantage was influenced by a group of patients who 
received long-term olaparib maintenance monotherapy. Biological factors that may 
predict these long-term responders are being investigated.18  
For the BRCAm subgroup, early separation of the Kaplan-Meier survival curves is 
evident, with maximal separation from a time point of approximately 48 months 
(Figure 2b). Mutations in BRCA1 and BRCA2 are the best characterised predictors 
of HRR deficiency in ovarian cancer. Our data support the proposed mechanism of 
action of olaparib as a synthetic lethality-inducing agent in the context of tumours 
with HRR deficiencies, such as BRCAm tumours. Ongoing translational analyses 
from Study 19 support the hypothesis that tumours with sBRCAm and gBRCAm are 
similar, both biologically and in sensitivity to olaparib.16 The OS data for sBRCAm 
patients were not inconsistent with those for gBRCAm patients, but the small size of 
the sBRCAm subgroup (n=20) limits the interpretation of our findings.  
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An exploratory restricted means analysis, using a pseudovalues methodology, 
showed a difference in restricted mean OS with olaparib compared with placebo of 
5·2 months in the overall population and 7·5 months in the BRCAm subgroup. Two 
other methodologies were investigated for the restricted means analysis 
(Supplementary Material, page 3) and all analyses gave comparable results, 
indicating an OS advantage with maintenance olaparib versus placebo, with a 
greater treatment effect in the BRCAm subgroup. The difference in median OS with 
maintenance olaparib compared with placebo was 2·0 months in the overall 
population and 4·7 months in the BRCAm subgroup. This is less than the difference 
in restricted mean OS; the mean offers an estimate of average life expectancy, 
which takes account of patients who do very well on treatment, whereas the median 
provides a more conservative estimate that is limited to the first half of the survival 
observations. For example, in the BRCAm subgroup who received olaparib, the 
median OS indicates that 50% of patients lived for longer than 34.9 months, but the 
mean survival time was 44.3 months.  
For the BRCAwt subgroup, some patients may have been HRR-deficient as a result 
of alternative factors, such as mutations in genes that encode other proteins involved 
in the HRR pathway, or epigenetic mechanisms, which do not yet have well-defined 
clinical testing strategies.19,20 Some separation is seen at the tail end of the BRCAwt 
survival curves for the two treatment groups (Figure 2c), suggesting that there may 
be a further subset of patients who receive benefit from olaparib treatment. 
Investigations into patients who were BRCAwt but deficient in other HRR genes are 
ongoing.21  
Study 19 was designed to demonstrate a statistically significant difference in PFS in 
the patients who were randomised: a population enriched for HRR tumours as a 
result of high-grade serous histology and platinum sensitivity. No rules were pre-
specified to control the Type 1 error rate for subgroups. The study was not designed 
to show a statistically significant difference in OS. However, a multiplicity strategy 
was pre-specified to control the error rate at 5% (two-sided) for multiple analyses of 
OS. Two previous OS analyses have been conducted, which did not meet statistical 
significance, and only 0·95% alpha (two-sided) was available to test at this updated 
analysis. The P-values did not meet this criterion for statistical significance 
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(P<0.0095) and therefore the favourable treatment effect observed for OS should 
only be considered descriptive and should be interpreted in the context of the 
clinically meaningful and statistically significant improvement in PFS. All P-values for 
OS are deemed nominal. The interpretation of the exploratory restricted means data 
is limited by the post-hoc nature of this analysis, as it was not pre-specified.  
The updated analyses for TFST and TSST show a significant improvement in these 
exploratory endpoints with olaparib in the overall study population, BRCAm and 
BRCAwt subgroups, consistent with the previous analysis.7 TFST is an exploratory 
endpoint but is clinically meaningful, as it represents the time that women are free 
from the next line of treatment. The updated TFST data provide a long-term view on 
efficacy, with the TFST Kaplan-Meier curves for the two treatment arms remaining 
clearly separated at a time point over 5 years from randomisation. As patients 
remain blinded to study treatment beyond progression, these data support an 
extended benefit, beyond PFS, for patients with PSR SOC receiving olaparib 
maintenance monotherapy. It can be challenging to understand the full therapeutic 
value of investigational treatments in ovarian cancer studies, as there is often a long 
follow-up for OS and analyses can be confounded by post-discontinuation therapy. 
Improvement in TSST can demonstrate continued benefit, beyond the next line of 
therapy, and this intermediate endpoint can therefore support other efficacy 
endpoints when evaluating the long-term impact of investigational treatments.22 
Crossover was not allowed in this study, but 17 patients from the placebo arm (14 
BRCAm patients) had received post-discontinuation PARPi treatment by the 2015 
DCO, via other clinical studies. This is considered to have had the potential to 
confound the OS data: an exploratory analysis has previously been reported for the 
BRCAm subgroup, excluding all patients from sites where at least one patient from 
the placebo arm received post-discontinuation PARPi therapy, and this showed a 
greater treatment effect than the previously published OS analysis.7,23 
Notably, at the DCO in 2015, there were 15 patients continuing on olaparib and one 
on placebo. Significant long-term exposure to maintenance olaparib was observed, 
with 18/136 (13%) of all patients (11/74 [15%] of BRCAm patients) receiving olaparib 
for ≥5 years. This observation supports the long-term benefit and tolerability of 
olaparib. Similar data for long-term treatment have not previously been seen in 
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clinical trials in recurrent ovarian cancer. Baseline data show that the majority of the 
19 patients who received study treatment for ≥5 years had two or three prior lines of 
chemotherapy and a platinum-free interval >12 months.  
Since the previous safety analysis, there has been an additional 3 years of follow-up, 
during which time no new safety signals were reported for the patients remaining on 
treatment and there was no change to the overall safety profile. For patients who 
received olaparib for ≥2 years, the most frequent AEs were not different to those in 
the overall population, specifically low-grade nausea, fatigue, constipation and 
vomiting, which are manageable and were generally reported prior to 2 years on 
treatment.6–8 These long-term safety findings are consistent with previous data from 
Study 19 and other clinical olaparib monotherapy studies. As reported in 2012, a low 
proportion of patients experienced AEs resulting in discontinuation of treatment.7  
To conclude, an OS advantage is seen for patients with BRCAm PSR SOC treated 
with olaparib as maintenance therapy in Study 19. This observation is consistent with 
data showing a significant improvement in PFS and in the intermediate endpoints 
TFST and TSST with olaparib. Additionally, 11 (15%) of 74 patients with BRCAm 
continued on olaparib for ≥5 years, highlighting that this PARPi can significantly alter 
the disease course. Ongoing analyses are investigating the potential benefit of 
olaparib for patients who are BRCAwt but have other HRR deficiencies, some of 
whom may continue on olaparib without progression for several years. There is an 
extensive Phase III clinical programme for olaparib, with the SOLO2 study 
(NCT01874353) assessing maintenance olaparib treatment (tablets) in BRCAm 





Research in context  
Evidence before this study 
We conducted searches of PubMed and the databases of the American Society of 
Clinical Oncology, European Society for Medical Oncology, Society of Gynecological 
Oncology and European Society of Gynaecological Oncology between 1 March 2015 
and 1 March 2016 to identify journal publications and meeting abstracts that included 
the search terms “poly(ADP-ribose) polymerase inhibitor” or “PARP inhibitor” and 
“ovarian cancer”. No language restrictions were used. Olaparib is an oral PARP 
inhibitor (PARPi) that has shown significant clinical activity and tolerability in patients 
with recurrent ovarian cancer and is approved in the EU and the US for the treatment 
of BRCA1/2-mutated advanced ovarian cancer. Other PARPis in clinical 
development include rucaparib, veliparib, niraparib and talazoparib. There have been 
no reports of an advantage in overall survival for ovarian cancer patients treated with 
maintenance therapy with a PARPi compared with placebo. 
Added value of this study 
This is the third overall survival analysis for a Phase II, randomised trial of olaparib 
maintenance monotherapy in patients with platinum-sensitive recurrent serous 
ovarian cancer (PSR SOC) and is, to our knowledge, the first analysis to indicate a 
survival advantage for patients with ovarian cancer treated with a PARPi. The 
survival analysis was conducted after more than 5 years total follow-up, at high data 
maturity, with an additional 3 years of follow-up since the previous analysis. The 
observed survival advantage may have primarily been driven by a survival benefit in 
the subgroup of patients with BRCA1/2 mutations (BRCAm). We believe this is also 
the first report of significant long-term exposure to a PARPi in recurrent ovarian 
cancer, with 18 (13%) of 136 patients receiving maintenance olaparib for ≥5 years. 
No new safety signals were observed and the long-term safety data were consistent 
with the known safety profile for olaparib monotherapy. 
Implications of all of the available evidence  
We have previously reported data from this Phase II study that showed a significant 
improvement in progression-free survival (PFS) with maintenance olaparib, with the 
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greatest benefit seen in patients with a BRCAm. Exploratory analyses have also 
shown a significant improvement in time to first and second subsequent therapy or 
death (TFST and TSST) with olaparib compared with placebo. To our knowledge, 
this is the first analysis to show survival data in recurrent BRCAm ovarian cancer 
that are consistent with previously reported benefits in PFS, TFST and TSST. Taken 
together, the available data support the long-term benefit and tolerability of 
maintenance olaparib in BRCAm patients with PSR SOC. 
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Figure 1. Enrolment, randomisation and treatment status at the third analysis of OS 
in Study 19.  
Footnote: DCO was on 30 September 2015. *One patient was randomly assigned to the placebo 
arm, but withdrew consent and withdrew from the study without receiving treatment 
 
Figure 2. OS in all patients and according to BRCAm status. a) All patients (n=265); 
b) BRCAm patients (n=136); c) BRCAwt patients (n=118). 
 
Figure 3. Summary of the Cox proportional hazards analysis of OS in the overall 
study population and different BRCAm subgroups. 
 
Figure 4. TFST and TSST in all patients and according to BRCAm status. a) TFST 
in all patients (n=264); b) TFST in BRCAm patients (n=136); c) TFST in BRCAwt 
patients (n=118); d) TSST in all patients (n=264); e) TSST in BRCAm patients 
(n=136); f) TSST in BRCAwt patients (n=118). 
 
Figure 5. Common AEs of all grades and grade ≥3 in patients who received study 
treatment for ≥2 years (olaparib n=32; placebo n=5).  
a) AEs reported from the start of treatment to the 2015 DCO* 
Footnote: *AEs that were reported in ≥8 patients are presented. Additional data for AEs in 
patients who received study treatment for ≥2 years are listed in the Supplementary Material (page 
4–5) 
b) AEs reported after 2 years*  
Footnote: *AEs that were reported in ≥4 patients are presented. Additional data for AEs reported 
after 2 years by patients who received study treatment for ≥2 years are listed in the 
Supplementary Material (page 6–7) 
 
 
 
 
